HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Marinus Pharma (NASDAQ:MRNS) and maintained a price target of $27.
August 11, 2023 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharma's stock is likely to be positively impacted by the reiterated 'Buy' rating and maintained price target of $27 by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence a company's stock price. In this case, the 'Buy' rating and $27 price target for Marinus Pharma by HC Wainwright & Co. is likely to instill confidence in investors and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100